SOURCE: Medical Marijuana, Inc.

CMW Media

December 20, 2016 09:00 ET

Medical Marijuana, Inc. Subsidiary HempMeds Brasil™ Welcomes Caroline Heinz to Executive Team

Ms. Heinz Joins HempMeds Brasil™ Team as New Director of Operations for Brazil-Based Company

SAN DIEGO, CA--(Marketwired - December 20, 2016) - Medical Marijuana, Inc. (OTC PINK: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that Caroline Heinz has been appointed as the new Director of Operations for their subsidiary, HempMeds Brasil™.

Heinz has played a vital role as part of the HempMeds Brasil™ team since its launch in 2014, working on brand development and marketing. Previous to her involvement with HempMeds Brasil™, Heinz worked in numerous high-level positions in various Brazilian and U.S. organizations such as world renowned media outlet TV Globo.

Ms. Heinz earned her Masters of Business Administration degree from San Diego University for Integrative Studies, and holds a Bachelor's degree in Social Communications from UNIVERCIDADE, in Rio de Janeiro, Brazil, majoring in Journalism.

"Ms. Heinz has been an integral part of the HempMeds Brasil™ team for many years now and we are very glad to announce her promotion Director of Operations for the company, a division of Medical Marijuana, Inc. (OTC PINK: MJNA)," said Chief Executive Officer, Dr. Stuart Titus. "When Real Scientific Hemp Oil™ (RSHO™) became the first medical cannabis product to be approved for import and use in Brazil, we knew that this was a huge opportunity and very important market for our company to be part of. We believe that Ms. Heinz has the talent to continue the upward momentum that HempMeds has in this emerging cannabinoid market within Brazil."

With the approval of RSHO™, Brazil also became the first Latin American country to approve prescriptions for any medical cannabis product, with Mexico and Paraguay following suit - issuing the first-ever approvals for Medical Marijuana, Inc. products in both countries.

"HempMeds Brasil™ has been instrumental in creating access to medical cannabis in Brazil, were we work with thousands of families in need of help gaining legal access to RSHO™," Heinz said. "I am beyond excited about taking on this new responsibility for a company that I fully believe in, which is working hard to educate the medical community and regulatory agencies to make the process for obtaining cannabis products like RSHO™ easier."

About HempMeds Brasil™

HempMeds Brasil™ currently has three cannabis products approved for importation into Brazil as a prescription medication for Epilepsy, Parkinson's and Chronic Pain. The company had the first-ever cannabis product allowed for import into Brazil and its products are currently subsidized by the Brazilian government, under their health care system, for all three medical indications listed above. HempMeds Brasil™ is working on additional approvals for multiple indications.

About Medical Marijuana, Inc.

Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s video statement, click here. Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.

LEGAL DISCLOSURE

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.

Contact Information